| 2025-12-02 |
Enterome |
Results Enterome OncoMimics™ immunotherapy EO2401 shows survival benefit in Phase 2 glioblastoma trial enterome.com ↗
The analyses demonstrated a statistically significant survival benefit for patients who underwent a second surgery after their first glioblastoma recurrence when treated with EO2401 in combination with nivolumab and bevacizumab, compared with patients who did not undergo surgery (p = 0.027). |
| 2023-11-20 |
Enterome |
Results Enterome’s OncoMimics™ Immunotherapy EO2401 Significantly Improves Survival Rate in Recurrent Glioblastoma enterome.com ↗
EO2401 continues to generate strong, durable, and target-specific immune responses associated with encouraging efficacy. |
| 2023-11-01 |
Enterome |
Results Enterome Presents Immune-Monitoring Data on EO2401 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) enterome.com ↗
EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1-19/SPENCER Study |
| 2023-10-23 |
Enterome |
Results Enterome Presents Positive Data from Phase 1/2 SPENCER Trial of EO2401 in Adrenal Tumors at ESMO 2023 Congress enterome.com ↗
|
| 2023-05-31 |
Enterome |
Results Enterome announces sustained positive clinical outcomes with EO2401, its lead OncoMimics™ immunotherapy, in combination therapy in Glioblastoma at ASCO enterome.com ↗
|
| 2022-11-10 |
Enterome |
Results Enterome’s OncoMimics™ peptide-based immunotherapy EO2401 generates and maintains elevated anti-tumor T cell responses for more than 10 months in patients with recurrent glioblastoma enterome.com ↗
These new data show that the memory CD8+ T cell response was found as early as two weeks after the first administration and that a strong and stable immune response continued to be detected for more than 10 months. |
| 2022-09-12 |
Enterome |
Results Enterome presents further efficacy data on its new generation therapeutic cancer vaccine EO2401 at ESMO Congress, demonstrating ability of OncoMimics™ antigens to generate positive clinical outcome enterome.com ↗
Follow-up data from Phase 1/2 clinical trials of EO2401 combined with nivolumab +/- bevacizumab in recurrent glioblastoma (ROSALIE study) and adrenocortical tumors (SPENCER study) demonstrate early and durable immune responses correlating to clinical outcomes |
| 2022-09-06 |
Enterome |
Results Enterome to present updates on EO2401, its first-in-class OncoMimics™ therapeutic cancer vaccine targeting solid tumors, at ESMO Congress 2022 enterome.com ↗
EO2401 is safe and well tolerated and generated immune responses in 35 out of 36 evaluable patients. |
| 2022-06-06 |
Enterome |
Results Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for glioblastoma, at ASCO 2022 enterome.com ↗
|
| 2022-06-06 |
Enterome |
Results Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for adrenocortical carcinoma, at ASCO 2022 enterome.com ↗
|
| 2022-05-19 |
Enterome |
Results Enterome to present world first clinical data with EO2401, its first-in-class off-the-shelf OncoMimics™ therapeutic cancer vaccine, at ASCO 2022 enterome.com ↗
Data highlights strong immune responses and early signs of clinical benefit, establishing proof-of-concept OncoMimics™ immunotherapy pipeline generated using Enterome’s unique microbiome Mimicry platform |